USPTO serial 79155336
VITROGRO
Reviewed by CopyMark Law Group
Reg. 4934476Status 404
- Filing date
- Status date
- Registration date
- Apr 12, 2016
- Examiner
- PHAM, LANA H
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with VITROGRO?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Rita E. Kline
RITA E KLINE TAROLLI SUNDHEIM COVELL & TUMMINO LLP1300 E 9TH STSTE 1700CLEVELAND, OH 44114Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | chemicals for use in science and industry, namely, biological tissue cultures other than for medical or veterinary purposes; biological products for use in science and industry, namely, a 3-dimensional living skin model comprising a de-cellurized de-epidermized dermis prepared from donor skin, for in vitro and in vivo scientific and research purposes and not for medical use, namely, investigating wound healing, pharmaceutics, toxicology, drug sensitivity, drug penetration and drug delivery, and recombinant therapeutic proteins for medical treatments; biochemicals, in the nature of proteins, for in vitro and in vivo scientific or research use, namely, vitronectin, fibronectin, insulin-like growth factor-I, insulin-like growth factor II, insulin-like growth factor binding proteins, epidermal growth factor, fibroblast growth factors, a combination of one or more of the foregoing proteins, portions of one or more of the foregoing proteins, and chimeric proteins containing any combination of the foregoing proteins or portions thereof; proteins for use in the manufacture of vaccines and bio-pharmaceuticals, namely, vitronectin, fibronectin, insulin-like growth factor-I, insulin-like growth factor II, insulin-like growth factor binding proteins, epidermal growth factor, fibroblast growth factors, a combination of one or more of the foregoing proteins, portions of one or more of the foregoing proteins, and chimeric proteins containing any combination of the foregoing proteins or portions thereof; kits containing biochemicals, namely, cell culture kits containing cell culture media and reagents for scientific and research use; biological products for use in science and industry, namely, biochemicals in the nature of proteins in raw form for cell culture and tissue engineering research, proteins for use in the clinical manufacture of vaccines, bio-pharmaceuticals, preparations for wound treatments, cell cultures and wound dressings; chemical reagents, namely, recombinant proteins for scientific and research use; chemicals for use in science and industry, namely, chemical preparations for cell culture for scientific and research use; chemical reagents, namely, biochemical reagents for scientific and research use and not for medical purposes; chemical reagents for scientific and research use and not for medical or veterinary purposes | SECTION 70 - CANCELLED | — |
| 005 | biological preparations, namely, spray-on skin and cultured skin grafts for burn treatment and reconstructive ophthalmic or bladder surgeries, and recombinant therapeutic proteins for medical treatment of burns, hard to heal wounds, surgically created wounds, and incisions; pharmaceutical preparations for treating burns and venous ulcers, wounds in diabetics, non-diabetic chronic wounds, surgical wounds, and to speed healing and improve recovery and scarring after ophthalmic and cosmetic surgeries; veterinary preparations for horses, cattle, pigs, cats and dogs for treating burns and venous ulcers, wounds in diabetics, non-diabetic chronic wounds, surgical wounds, and to speed healing and improve recovery and scarring after ophthalmic and excisional surgeries; chemical preparations for cell culture for medical purposes, namely, for wound treatment; chemical reagents for medical use; biochemical reagents for medical use; recombinant proteins for medical use, namely, for use in cell culture autologous treatments, and for the treatment of burn and venous ulcer wounds, diabetic wounds, non-diabetic chronic wounds, surgical wounds, and to speed healing and improve recovery and scarring after surgery; biological preparations for medical use, namely, vitronectin, fibronectin, insulin-like growth factor-I, insulin-like growth factor II, insulin-like growth factor binding proteins, epidermal growth factor, fibroblast growth factor, a combination of one or more of the foregoing proteins, portions of one or more of the foregoing proteins, and chimeric proteins containing any combination of the foregoing proteins or portions thereof, for the treatment of burn and venous ulcer wounds, diabetic wounds, non-diabetic chronic wounds, surgical wounds, and to speed healing and improve recovery and scarring after surgery; biological tissue culture media for use in skin cell culture used for medical purposes; pharmaceutical preparations for skin care used for treating burns, venous ulcers, diabetic wounds, non-diabetic chronic wounds, surgical wounds, and to speed healing and improve recovery and scarring after ophthalmic and cosmetic surgeries, and for improving the appearance of wrinkles and skin defects; medical dressings, surgical dressings, wound care components, namely, wound and surgical dressings; surgical implants, namely, arterial grafts; drugs, namely, topical creams, gels and sprays for medical purposes for treating burns, venous ulcers, diabetic wounds, non-diabetic chronic wounds, surgical wounds, and to speed healing and improve recovery and scarring after ophthalmic and cosmetic surgeries; drugs, namely, topical creams, gels and sprays for veterinary purposes for use on horses, cattle, pigs, cats or dogs for treating burns, venous ulcers, diabetic wounds, non-diabetic chronic wounds, surgical wounds, and to speed healing and improve recovery and scarring after ophthalmic and excisional surgeries; vaccines | SECTION 70 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Tissue Therapies Limited
- Other trademarks owned by Tissue Therapies Limited
- Other trademarks owned by Tissue Therapies Limited
- Other trademarks in Class 001
- Other trademarks in Class 005
- Similar marks named VITROGRO
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| May 3, 2019 | DENC | NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG E-MAILED | — |
| May 3, 2019 | DETH | DEATH OF INTERNATIONAL REGISTRATION | — |
| May 19, 2017 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Jul 28, 2016 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Jul 13, 2016 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Jul 13, 2016 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Jul 12, 2016 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Apr 12, 2016 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jan 26, 2016 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jan 26, 2016 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jan 22, 2016 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Jan 6, 2016 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Jan 6, 2016 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Jan 6, 2016 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Dec 22, 2015 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Dec 15, 2015 | ALIE | ASSIGNED TO LIE | — |
| Dec 2, 2015 | EXPT | EXPARTE APPEAL TERMINATED | — |
| Dec 2, 2015 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Oct 29, 2015 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Oct 29, 2015 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Oct 22, 2015 | ALIE | ASSIGNED TO LIE | — |
| Oct 1, 2015 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| Oct 1, 2015 | EXPI | EX PARTE APPEAL-INSTITUTED | — |
| Oct 1, 2015 | JURT | JURISDICTION RESTORED TO EXAMINING ATTORNEY | — |
| Oct 1, 2015 | EXAF | EXPARTE APPEAL RECEIVED AT TTAB | — |
| Apr 7, 2015 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Apr 7, 2015 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Apr 7, 2015 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Mar 11, 2015 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Mar 11, 2015 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Mar 11, 2015 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Feb 23, 2015 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Feb 23, 2015 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Jan 8, 2015 | RFNT | REFUSAL PROCESSED BY IB | — |
| Dec 19, 2014 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Dec 19, 2014 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Dec 19, 2014 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Dec 18, 2014 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 11, 2014 | DOCK | ASSIGNED TO EXAMINER | — |
| Nov 28, 2014 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Nov 24, 2014 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Nov 21, 2014 | LIMI | LIMITATION FROM ORIGINAL APPLICATION ENTERED | — |
| Nov 20, 2014 | SDRC | SN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB | — |